Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing and treating brain tumors often requires invasive surgical biopsies, which carry significant risks and may not always provide a complete picture of the tumor's genetic makeup. Traditional diagnostic methods can also be slow, delaying the start of appropriate treatment.
Solution
Exsegen Genomics offers both non-invasive liquid biopsy and NGS-based tissue biopsy services to improve brain tumor diagnostics and treatment planning. The liquid biopsy utilizes AI/ML algorithms to analyze DNA, RNA, or protein data from a blood sample, providing a less invasive alternative to surgical biopsy with rapid results. The tissue biopsy employs advanced sequencing technology and proprietary algorithms to analyze tumor tissue samples, offering detailed genetic insights. Both methods aim to provide comprehensive genomic profiling for personalized treatment plans and early detection.
Target Audience
The primary target audience includes neurosurgeons, oncologists, and other healthcare professionals involved in the diagnosis and treatment of brain tumors.
Features
- Liquid biopsy diagnostics using AI/ML analysis of blood samples (CTC, cfDNA, or exosomes)
- NGS-based tissue biopsy for comprehensive genomic profiling of brain tumors
- DNA methylation testing for difficult-to-diagnose tumors
- Patented similarity match using AI/ML algorithms to compare samples with a large database of analyzed tumors
- Identification of targetable gene fusions and mutations
- Microsatellite instability (MSI) detection as a marker for immunotherapy efficacy
- Histopathology reporting on a standardized digital pathology platform
- Custom-built brain tumor NGS panel that detects relevant mutations, gene fusions, and copy number variations
- Sequencing depth of >500x, compliant with WHO recommendations